Liver neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The short-term iron imbalance initiated by AFP promoter regulation only occurred in hepatoma cells, resulting in signal contrast on MRI.
|
31118631 |
2019 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The DBS-based method for the measurement of cancer biomarkers may also be applied to several other chronic diseases with increased risks of αFP-producing liver tumors.
|
30646549 |
2019 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
One-shot transfusion of hepatoma serum to naïve rats induced liver cancer development with gradual elevation of alpha-fetoprotein (AFP), but exosome-free hepatoma serum failed to induce AFP elevation.
|
31162867 |
2019 |
Liver neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A 48-year-old male patient was admitted to our hospital under suspicion of an advanced liver tumor due to an increase in levels of alpha-fetoprotein (AFP) after radiofrequency ablation for independent nodule in his liver 1 month before.
|
31045756 |
2019 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hepatoma arterial-embolization prognostic (HAP) score and its modifications (modified HAP [mHAP] and mHAP-II), consisting of some or all of the following factors of tumor size, number, alpha-fetoprotein, bilirubin, and serum albumin, have been found to predict outcomes after trans-arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).
|
30991968 |
2019 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Multivariate analysis identified high HMGB1 at 4 weeks (P = 0.001), high α-fetoprotein (AFP) at baseline (P = 0.025), tumor liver occupying rate (P = 0.009) and modified RECIST (mRECIST, P < 0.0001) as independent predictors of poor overall survival in sorafenib treatment.
|
28474222 |
2018 |
Liver neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We compared the patient characteristics, the serum alpha-fetoprotein level, and the tumor-liver contrast (TLC) of the main tumor on dCT scans of both groups.
|
29101449 |
2018 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, the effects of anti-human AFP antibody on the functions of PTEN were examined using an AFP-producing human hepatoma cell line.
|
28498467 |
2017 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Alpha-fetoprotein (AFP) is widely used as a tumor marker for the serum diagnosis of primary hepatoma.
|
28454733 |
2017 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Due to good drug-loading, high encapsulation ratio, and highly selective affinity for AFP-positive tumors, the (131)I-antiAFPMcAb-GCV-BSA-NPs are promising for further effective radiation-gene therapy of hepatoma.
|
26981334 |
2016 |
Liver neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Icaritin inhibits the expression of alpha-fetoprotein in hepatitis B virus-infected hepatoma cell lines through post-transcriptional regulation.
|
27835879 |
2016 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Effects of curcumin in pediatric epithelial liver tumors: inhibition of tumor growth and alpha-fetoprotein in vitro and in vivo involving the NFkappaB- and the beta-catenin pathways.
|
26515460 |
2015 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results indicate cytoplasmic AFP is not only a histochemical tumor biomarker for human hepatoma but is also an intracellular signal molecule and potential participant in HBx induced hepatocarcinogenesis.
|
25846475 |
2015 |
Liver neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The hepatoma cell model HepG2 which had a stable expression of AFP gene was used.
|
24425104 |
2014 |
Liver neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
First, pAFPS-Luc or pAFPL-Luc vector was constructed with the alpha-fectoprotein (AFP) promoter and enhancer for hepatoma tissue specific gene expression.
|
23830978 |
2013 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
AFP enhancer/pgk promoter-driven expression of the dominant negative form of the PP2A catalytic subunit α (DN-PP2Acα) exerted cytotoxic effects against an AFP-positive human hepatoma cell lines (HepG2 and Hep3B), but did not affect AFP-negative human hepatoma cells (SK-HEP-1) or normal human liver cells (L-02).
|
23173703 |
2012 |
Liver neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Impact of intracellular alpha fetoprotein on retinoic acid receptors-mediated expression of GADD153 in human hepatoma cell lines.
|
21365646 |
2012 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor-targeted gene therapy using Adv-AFP-HRPC/IAA prodrug system suppresses growth of hepatoma xenografted in mice.
|
21959967 |
2012 |
Liver neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We aimed to take advantage of the dramatic re-expression of the Afp gene in HCC to develop a hepatocarcinogenesis reporter (HCR) mouse model for dual-modality, longitudinal in vivo imaging of liver tumor development, and progression.
|
21354236 |
2011 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, Ad·AFP·D55-TRAIL could be a potential anti-hepatoma agent with anti-tumor activities due to AFP-specific replication and TRAIL-induced apoptosis.
|
21412282 |
2011 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ad/AFPtBid did not suppress the hepatic tumor formed by non-AFP-producing hepatoma SK-HEP-1 cells or colorectal adenocarcinoma DLD-1 cells.
|
20336154 |
2010 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hence, the present commentary was divided into two sections; (1) the characterization, properties, and traits of AFP peptide epitopes, and (2) the use of AFP-derived peptides in the therapeutic induction of T cells primed against hepatoma cells using both in vivo and in vitro models.
|
18612637 |
2009 |
Liver neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These results demonstrate that the AdPLEN vector can function in high AFP expression hepatoma cells.
|
19241193 |
2009 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A tumor-specific chimeric promoter for alpha-fetoprotein gene (AFP) was combined with hepatitis B virus (HBV) enhancer II to investigate radioiodine uptake in vitro and in vivo in hepatoma (HepG2) and nonhepatoma (ARO) cell lines after transfer of hNIS gene.
|
19331152 |
2009 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We conclude that ATRA or TRAIL resistance in AFP producing hepatoma is at least, in part, attributable to the high level of the cytoplasmic AFP.
|
19267404 |
2009 |